CARBIOS
26.1.2023 06:46:34 CET | Business Wire | Press release
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005432/en/
(L-R): Martine BRISSET (General Manager Biodegradation Division, Senior Vice President of Carbios Group, and Executive Committee Member) and Delphine DENOIZE (Innovation Programs Funding, Regulation and LCA Director, and Executive Committee Member)
Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies for reinventing the life cycle of plastics and textiles, has strengthened its leadership team with the appointment of Martine BRISSET as Senior Vice President from 1 January 2023. Martine will manage the Biodegradation Division and supervise the Human Resources, Legal, Regulatory, Project Management, Quality Health and Safety departments. Martine BRISSET joins the Group's Executive Committee, as does Delphine DENOIZÉ, who remains Innovation Programs Funding, Regulation and LCA Director with an expanding team.
"Over the past six months, our teams have grown significantly in order to achieve our ambitious targets, and I am very pleased to appoint Martine and Delphine to the Executive Committee," commented Emmanuel LADENT, Chief Executive Officer of Carbios. "Their proven track records, notably within the Carbios Group, strengthen the top management’s expertise and reinforces the diversity of skills needed to succeed in this pivotal year for Carbios’ industrialization and commercialization.”
Martine BRISSET, Senior Vice President of Carbios : “After having supervised the production of thousands of tons of plastic destined for the packaging sector, I am now focused on reducing plastic pollution with our biodegradation and biorecycling solutions. I'm very excited to take on this awesome and exciting challenge, one that makes sense for future generations and for industry."
Martine BRISSET has over 30 years of General Management experience in major international groups within the plastic and paper packaging industry, most notably at Amcor, Huhtamaki, Linpac and Klockner Pentaplast. Since 2021, she has held the position of General Manager of Carbiolice in order to integrate this high-potential subsidiary dedicated to biodegradation within the Carbios Group. In her new position as Senior Vice President of Carbios, her main mission will be to successfully deploy the biodegradation technology, facilitate the international expansion of Carbios' activities, organise the recruitment and training of the Group's employees. With numerous recruitments planned throughout the company in 2023, building Carbios’ attractivity will be a strategic topic.
Delphine DENOIZÉ, Innovation Programs Funding, Regulation and LCA Director : "What drives me is the satisfaction of seeing a project through, from concept to reality. At Carbios, all our projects have a positive impact on the environment, and it’s rising to this challenge that makes me passionate about my work. By becoming a member of the Executive Committee, I will support these projects even more enthusiastically, in terms of their structuring and funding, but also in terms of their regulatory compliance and environmental performance.”
After several years working in innovation within the agricultural industry, it was during her time at Céréales Vallées cluster that Delphine DENOIZÉ discovered and assisted in the creation of Carbios. She joined the company in 2016 and was one of its first twenty employees. Initially in charge of Innovation Funding and Regulation, then Project Management for PET biorecycling, she now oversees all the Group’s projects. Her responsibilities include French and European public funding for innovation, regulatory compliance of processes and products around the world, and assessment of their environmental impact through specific tools such as Life Cycle Assessment.
Executive Committee Members of Carbios Group:
- Emmanuel LADENT, Chief Executive Officer
- Lionel ARRAS, Industrial Development Director
- Mathieu BERTHOUD, Sourcing and Public Affairs Director
- Pascal BRICOUT, Chief Strategy and Financial Officer
- Martine BRISSET, General Manager Biodegradation Division and Senior Vice President of Carbios Group
- Delphine DENOIZÉ, Innovation Programs Funding, Regulation and LCA Director
- Stéphane FERREIRA, Chief Business Officer
- Lise LUCCHESI, Intellectual Property Director
- Prof. Alain MARTY, Chief Scientific Officer
Visit Carbios’ website for biographies of each individual member: https://www.carbios.com/en/governance/
About Carbios
Established in 2011 by Truffle Capital, Carbios is a green biotech company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published in front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.
In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products.
The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperatures, even in domestic conditions, integrating enzymes at the heart of the plastic product.
For more information, please visit carbios.com / Twitter: Carbios / LinkedIn: Carbios / Instagram: insidecarbios
Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.
Translation is for information purposes only.
In case of discrepancy between the French and the English version of this press release, the French version shall prevail
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
